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Abstract
Background: Eradication of HIV-1 from an infected individual cannot be achieved by current drug
regimens. Viral reservoirs established early during the infection remain unaffected by anti-retroviral
therapy and are able to replenish systemic infection upon interruption of the treatment.
Therapeutic targeting of viral latency will require a better understanding of the basic mechanisms
underlying the establishment and long-term maintenance of HIV-1 in resting memory CD4 T cells,
the most prominent reservoir of transcriptional silent provirus. However, the molecular
mechanisms that permit long-term transcriptional control of proviral gene expression in these cells
are still not well understood. Exploring the molecular details of viral latency will provide new
insights for eventual future therapeutics that aim at viral eradication.
Results: We set out to develop a new in vitro HIV-1 latency model system using the doxycycline
(dox)-inducible HIV-rtTA variant. Stable cell clones were generated with a silent HIV-1 provirus,
which can subsequently be activated by dox-addition. Surprisingly, only a minority of the cells was
able to induce viral gene expression and a spreading infection, eventhough these experiments were
performed with the actively dividing SupT1 T cell line. These latent proviruses are responsive to
TNFα treatment and alteration of the DNA methylation status with 5-Azacytidine or genistein, but
not responsive to the regular T cell activators PMA and IL2. Follow-up experiments in several T
cell lines and with wild-type HIV-1 support these findings.
Conclusion: We describe the development of a new in vitro model for HIV-1 latency and discuss
the advantages of this system. The data suggest that HIV-1 proviral latency is not restricted to
resting T cells, but rather an intrinsic property of the virus.
Background
With the introduction of highly active antiretroviral ther-
apy (HAART) against HIV-1 it has become possible to sta-
bly reduce the viral load below the detection limit in most
patients (reviewed in [1]). Current therapies target various
steps of the virus replication cycle but can only prevent
new infections, without an impact on already infected
cells or the integrated provirus. Clearance of infected cells
is possible only by cell death or recognition by the host
immune system. Consequently, HIV-1 can persist in long-
lived reservoirs of different cell types. These cellular reser-
voirs may differ in the magnitude of viral latency, ranging
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from low-level virus production that does not trigger
immune recognition to truly latent proviruses [2-7]. Viral
infection of resting and quiescent cells can lead to a pre-
integration complex that fails either to complete reverse
transcription or to integrate. These complexes are stable
for only a few days and are therefore not important for
long term latency [8-11]. Another component of the reser-
voir consists of productively infected lymphocytes (CD4+
T cells) that reverted from an activated state to a quiescent
state as a consequence of establishing immunological
memory [2]. In the resting state, these cells fail to produce
virus, but these proviruses can be reactivated later on [8-
12]. These resting T cells persist with an average half-life of
44 months [13], and it can be estimated that it will take
more than 60 years to eradicate this reservoir [14].
Numerous attempts have been made to activate these
latently infected cells in order to expose these viral reser-
voirs to antiviral drugs, thus far with limited success in
patients [2].
A key determinant for viral transcription after proviral
DNA integration is the status of cellular transcription fac-
tors that activate the basal LTR promoter to express the
viral Tat protein that induces an autoregulatory expression
loop. Tat binds to the TAR RNA hairpin encoded by the
LTR and recruits the cyclin T1-CDK9 complex to enhance
viral transcription [15-18]. The HIV-1 subtypes each
encode a unique set of transcription factor binding sites in
their LTR, suggesting the intriguing possibility that the
subtypes differ in their latency profile [19,20]. In addition
it has been demonstrated that unfavorable proviral inte-
gration sites can also result in low level basal transcription
and cause latency [21,22].
An important obstacle in latency research is the lack of a
good experimental model system. Patient samples are not
well suited for analysis since latently infected cells can
hardly be distinguished phenotypically from uninfected
cells. The presence of proviral DNA is an obvious differ-
ence, but there are currently no validated methods to
quantify or select these cells. It is also difficult to distin-
guish cells with defective versus latent proviruses,
although reactivation is an option [2,23]. In vitro studies
frequently use the latently infected cell lines U1 and ACH-
2, although latency is caused by mutational disruption of
the regular Tat-TAR axis [2,24,25]. As an alternative, J-Lat
cells were selected for lack of GFP expression from a pro-
viral construct, which could be activated by TNFα treat-
ment [21].
In this study, we used the doxycycline (dox) dependent
HIV-rtTA variant [26-28] to generate a new HIV-1 latency
model. We constructed stable cell lines with a HIV-rtTA
provirus that is completely dependent on dox for virus
production. This inducible, fully replication competent
virus forms an ideal tool to study certain aspects of provi-
ral latency. With wild-type HIV-1, one cannot stop ongo-
ing virus replication that eventually kills the host cell.
With HIV-rtTA, it is possible to freeze the proviral state by
dox withdrawal and subsequent reactivation can be done
at will by simple dox addition. Surprisingly, we measured
a high degree of HIV-rtTA proviral silencing in the actively
dividing T cell line SupT1. With clone-to-clone variation,
only 0.1–10% of the provirus containing cells can be
induced to express virus. Reactivation of these proviruses
was possible by activation of the NF-κB pathway and by
influencing genomic DNA methylation. Follow-up exper-
iments in several other T cell lines and with wild-type
HIV-1 support these findings. These results indicate that
HIV-1 latency is established frequently in actively dividing
cells.
Results
Strong silencing of HIV-rtTA in SupT1 T cells
We used the dox-dependent HIV-rtTA virus to study HIV-
1 latency (Fig. 1)[27]. In this conditional live virus, the
normal Tat-TAR transcriptional axis has been replaced by
components of the Tet-On system, but the regular HIV-1
promoter elements are conserved [29,30]. Infection of
cells in the absence of dox will allow the establishment of
a transcriptionally silent provirus as a new model for HIV-
1 latency. Subsequent dox-addition will activate the pro-
virus on command. We recently used this virus to con-
struct the HIV-rtTA-shNef variant with a polymerase III
(Pol-III) driven shRNA expression cassette that targets the
wild-type HIV-1 nef gene, which is lacking in this con-
struct (Fig. 1). This shRNA is produced constitutively
whereas the viral LTR promoter is under dox-control.
Consequently, the shNef-producing cells with this induc-
ible provirus should be protected against wild-type HIV-1
infection. We produced 24 cell clones derived from the
SupT1 T cell line upon HIV-rtTA-shNef infection and
demonstrated resistance to subsequent HIV-1 challenge in
most clones (Table 1, third column). However, five of the
24 cell clones remained sensitive to HIV-1 superinfection
and further analysis indicated that transcriptional silenc-
ing of the Pol-III cassette may have occurred [31].
To expand on this putative silencing effect we analyzed
HIV-rtTA virus production and replication in all 24
clones. An HIV-1 specific PCR on genomic DNA con-
firmed that all cell lines have at least one provirus (Table
1, second column). Prolonged culturing of these clones
with dox demonstrated that 13 clones produce replica-
tion-competent HIV-rtTA virus, but 11 clones are unable
to initiate a spreading virus infection. The positive clones
are grouped in the bottom part of Table 1. The percentage
of cells with a dox-inducible provirus was analyzed by
intracellular staining for the CA-p24 protein after 24 hRetrovirology 2008, 5:37 http://www.retrovirology.com/content/5/1/37
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and 48 h dox-induction (Table 1). To avoid multiple
rounds of infection, we added the potent fusion inhibitor
T1249. Surprisingly, only few cells of the clonal cultures
responded to dox addition, ranging from 0% to approxi-
mately 10% of the cells in clone F7 (Table 1). In general,
a correlation between CA-p24 production and HIV-rtTA
replication was observed, with few exceptions. The clones
that do not support dox-induced virus replication also
lack any detectable CA-p24 production, with the excep-
tion of clone B8. An obvious explanation of this phenom-
enon is the presence of a defective provirus that would
prevent virus production, although a frequency of 11 out
of 24 clones seems very high. Most importantly, among
the 13 clones that do contain a viable and replication-
competent provirus, only a minority of the cells (0–10%)
is able to produce virus after dox administration, suggest-
ing massive silencing of the HIV-rtTA-shNef provirus in
the SupT1 T cell line.
We screened several of the HIV-resistant cell clones for
shRNA expression by Northern blot analysis (Fig. 2). We
observed a quite variable expression level among the
clones, indicating that a relative low shRNA level is suffi-
cient to block wild-type virus replication. There was no
significant correlation between the level of Pol-III driven
shRNA expression and the level of Pol-II driven CA-p24
production. We thusfar only discussed the percentage of
cells that start producing CA-p24 upon dox-addition as a
measure of proviral latency. In fact, we also scored the
absolute level of CA-p24 production in positive cells from
the different clones, but measured very similar expression
levels (Table 1). Interestingly, this rather uniform CA-p24
expression level in HIV-producing cells from different
clones indicates that the intrinsic transcriptional activity is
determined by the provirus itself and relatively independ-
ent of the integration locus. This makes sense as it may be
important for the virus to reach a precisely fine-tuned
level of gene expression for optimal virus production.
Consistent with this idea, we observed promoter modula-
tion in virus evolution experiments [32].
Schematic overview of HIV-1 variants used in this study Figure 1
Schematic overview of HIV-1 variants used in this study. In the HIV-rtTA variant, the rtTA gene is inserted in place of 
the nef gene and TetO binding sites are inserted in the HIV-1 promoter. Inactivation of the Tat-TAR axis is obtained by muta-
tions in the R region and the Tat protein. The shNef expression cassette is inserted in the U3 region. The Tat inactivating 
mutation (indicted by X) in HIV-rtTA has been restored in the HIV-rtTA Tatwt variant.
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Activation of latent HIV-rtTA provirus
To analyze if dox-induction of the integrated HIV-rtTA
provirus is prohibited by silencing/latency of the HIV LTR
promoter we tried to activate the provirus in these cells.
We tested regular T cell activators, demethylation inducers
and cell cycle blockers. TNFα induces activation of the NF-
κB pathway, which plays an important role in reactivation
and preventing HIV-1 latency [2,14,21,33,34]. 5-azacyti-
dine (5-Aza) causes demethylation of genomic DNA and
can overcome latency. Genistein induces a G2 arrest, stim-
ulates lentiviral gene transfer [35] and HIV-1 replication
[36]. These compounds were tested individually and in
combination. We determined the percentage of CA-p24
positive cells after 24 h dox-induction with or without
these effectors. This analysis was performed on the high-
producer SupT1 cell clone F7 and the low-producer clone
B9. TNFα increases the percentage of CA-p24 producing
cells upon dox-induction 5-fold for the clone F7 and more
than 24-fold for clone B9, thus boosting the percentage of
positive cells in both cases to approximately 20% (Fig 3).
In other words, the impact of activation is more pro-
nounced in the restricted cell clone B9 compared to the
high-producer clone F7. Genistein and 5-Aza also partially
resolve the proviral latency, suggesting that expression
from a HIV-rtTA provirus can be triggered through multi-
ple routes. Regular T cell activators like IL2 and PHA do
not increase the fraction of HIV-rtTA producing cells in
response to dox. A particular potent combination to avoid
latency is TNFα with genistein, yielding approximately
50% positive cells for both the F7 and B9 clones. The
effectors genistein, 5-Aza and TNFα also seem to have a
positive effect on basal gene expression from the HIV-rtTA
provirus without dox, but the low percentage of CA-p24
positive cells (≤ 0.01%, results not shown) does not allow
accurate measurements.
The ability to activate a provirus is likely related to the spe-
cific integration site and the number of proviruses. The
integration sites in the different clones were identified by
linker mediated PCR [37] and/or inside-out PCR [38].
Despite the use of two different techniques, it was not pos-
sible to identify the actual integration sites for all clones.
Table 1: Overview of SupT1 clones with integrated HIV-rtTA provirus
Clone HIV-rtTA gDNA PCR HIV-1 resistant1 Dox-induced Number detected proviruses
HIV-rtTA replication2 Intracellular CA-p243
(24 h) (48 h) M.F.I.5
B5 + - - 0.01 0.04 - -4
B8 + - - 0.38 0.34 62 -
C2 + + - 0.04 0.00 - 1
C4 + + - 0.01 0.00 - -
C7 + + - 0.00 0.00 - 2
D2 + + - 0.01 0.06 - 1
D10 + - - 0.01 0.02 - -
D11 + + - 0.02 0.01 - 1
E4 + + - 0.00 0.01 - 2
F3 + - - 0.00 0.01 - -
H7 + + - 0.00 0.00 - 3
B4 + + + 0.38 0.50 70 1
B6 + + + 0.22 0.19 78 5
B9 + + + 1.34 1.66 69 3
C5 + + + 0.72 0.82 106 3
C11 + + + 0.01 0.04 - 3
D4 + + + 0.07 0.02 - 4
D6 + + + 0.07 0.02 - 1
E7 + + + 0.43 0.59 100 -
E11 + + + 0.05 0.02 - -
F7 + + + 10.52 11.54 49 2
F8 + + + 1.31 2.16 82 1
F9 + - + 0.07 0.02 - 1
G2 + + + 0.02 0.01 - 1
1 Wild-type HIV-1 LAI superinfection
2 HIV-rtTA replication scored by syncytia formation and extracellular CA-p24 production
3 Percentage CA-p24 positive cells
4 -; not detected
5 M.F.I. is the mean fluorescence intensity of the CA-p24 positive cells (48 h dox)Retrovirology 2008, 5:37 http://www.retrovirology.com/content/5/1/37
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Thus, the number of 1 to 5 integration sites in the clones
should be regarded as a minimal estimate. The presence of
multiple proviruses will make the cell less likely to exhibit
the latency phenotype. No strict correlation was apparent
between dox inducibility and the number of HIV-1 provi-
ruses, but inspection of the data in Table 1 suggests a trend
towards more proviruses in the group that allows HIV-
rtTA replication (gray panel in the bottom part of Table 1).
On average, the number of detected proviruses in this
group is 1.9 (range 0–5) versus 0.9 (range 0–3) in the
non-producer cell clones. We also analyzed specific char-
acteristics of the integration sites (chromosome number,
gene density, intra- versus inter-genic, proximity to tran-
scription start sites, proximity to CpG Islands) but did not
notice any striking trend between high- versus low-CA-
p24 producing cell clones.
HIV-rtTA with an active Tat protein also demonstrates 
latency
The latency phenotype in SupT1 cells may be a specific
property of the HIV-rtTA variant virus. For instance, this
virus variant encodes a mutant Tat protein (Tyr26Ala) that
is unable to support Tat-mediated transcription [39]. To
test this possibility, we also generated SupT1 clones with
an integrated HIV-rtTA variant that encodes a wild-type
Tat protein. We found that all clones exhibit a similarly
low percentage of CA-p24 producing cells upon dox-
induction as observed for the Tat-minus HIV-rtTA variants
(results not shown). Thus, a wild-type Tat protein cannot
prevent the establishment of proviral latency, although
one should realize that Tat production will be minute in
the absence of dox. Alternatively, during selection of the
clones, there is no transcription from the HIV-rtTA pro-
moter and this could theoretically result in active silenc-
ing of the provirus and subsequently block dox activation.
However, we observed the same phenomenon when the
HIV-rtTA or HIV-rtTA Tatwt clones were generated in the
absence or continuous presence of a low level of dox
(results not shown).
Latency effects of wild-type HIV-1 in SupT1 cells
To establish if the observed latency is also seen for wild-
type HIV-1, we set up a single round infection system with
the HIV-1 LAI isolate in the SupT1 cell line. Multiple
rounds of infection were prevented by addition of T1249
at 2 h after infection. After 24 h, the infected culture was
split in two and TNFα was added to one culture. Intracel-
lular CA-p24 staining was performed after another 24 h.
We measured a 3-fold increase of the percentage of virus
producing cells in the presence of TNFα, indicating pro-
found silencing without activation of the T cell line (Fig.
4A). We should point out that this experiment is more dif-
ficult to interpret than the previous HIV-rtTA analyses. For
instance, it is possible that TNFα addition has other stim-
ulatory effects on the infection process, e.g. reverse tran-
scription or integration rather than on reducing latency.
To exclude these possibilities, the TNFα induction was
repeated with the control culture 7 days after the initial
infection. Again, TNFα increased the percentage of virus
producing cells 2- to 3-fold (Fig. 4B). The results indicate
that infection of SupT1 cells with wild-type HIV-1 fre-
quently results in the establishment of a latent provirus.
In the single-round infection experiments with wild-type
HIV-1, it is not easy to determine the frequency of latent
versus active proviruses. With a low multiplicity of infec-
tion, only a small percentage of the cells will be infected
and this results in unreliable FACS data. With a higher
multiplicity of infection, cells are likely to contain multi-
ple proviruses and a single active provirus will domi-
nantly mask multiple silent proviruses. With the cell clone
experiments that are possible with the HIV-rtTA virus, we
found a very high frequency of latent proviruses. To
directly compare latency properties of the wild-type and
HIV-rtTA virus, the single round infection experiment was
repeated with both viruses. A similar increase in the per-
centage of virus producing cells was observed upon TNFα
addition (Fig. 5), indicating similar latency frequencies.
Northern blot analysis of shRNA production in rtTA-shNef  SupT1 cell lines Figure 2
Northern blot analysis of shRNA production in rtTA-
shNef SupT1 cell lines. RNAs from the different HIV-
rtTA-shNef SupT1 clones were isolated and separated on an 
agarose gel. After blotting the membrane was probed with a 
LNA probe against the shNef. Lane M, marker; lane 1, shNef 
clone B9; lane 2, clone C10 (a negative control cell line with-
out a provirus); lane 3, shNef clone D2; lane 4, shNef clone 
D11; lane 5, shNef clone F7; lane 6, shNef clone F8; lane 7 
and 8 contain positive controls from a transfection with the 
F-shNef- and F-shNef+ plasmid [31]; lane 9 contains a negative 
empty-vector control; lane 10 in vitro produced shNef RNA.
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To broaden the analysis of this latency phenotype, we
used other T cell lines in single round infections with the
wild-type HIV-1 LAI isolate. TNFα also increased the per-
centage of CA-p24 positive Jurkat cells, but no such effects
were observed in the HTLV-1 transformed T cell lines
C8166 and MT2, and in PHA/IL2 activated CD4+ T lym-
phocytes (Fig. 6). These results indicate that TNFα medi-
ated latency suppression might be cell type specific.
Discussion
We previously constructed a unique HIV-1 variant in
which the Tat-TAR transcription motifs were inactivated
and replaced by the inducible Tet-On system [27]. In this
study, this HIV-rtTA virus was used to generate cell lines
with a dox-controllable HIV provirus. These cell lines har-
bor a silent provirus that is completely dependent on dox
addition for activation but that contains the original tran-
scription factor binding sites in the HIV-1 LTR promoter
for regulated transcription. An additional important
advantage of this system is that no selection was used to
obtain these cell lines, thus avoiding any bias towards cer-
tain activation markers. These clonal cell lines are there-
fore an ideal tool to study HIV-1 transcriptional latency.
We screened these cell lines for dox-induced intracellular
CA-p24 production by FACS analysis. This allows us to
discriminate at the cellular level between active and silent
proviruses.
A surprising observation was that, although experiments
were performed in the actively dividing T cell line SupT1,
only 0.1–10% of the cells is able to produce CA-p24 after
dox addition. These results indicate that HIV-1 latency is
not restricted to non-dividing cells, but apparently also
frequently occurs in actively dividing cells. In fact, it seems
that the establishment of proviral latency is the default
pathway in the SupT1 T cell line. The results with the Jur-
kat T cell line confirm this idea. It could be argued that
silencing is induced because our HIV-rtTA variant will be
transcriptionally silent as long as we do not provide dox.
However, no difference in viral infectivity was scored
between single round infections in which dox was contin-
uously present or added at later time points (17 h, 41 h).
We do not think that this observation is unique for the
dox-inducible HIV-rtTA virus since we also measured a
Silencing and reactivation in HIV-rtTA SupT1 cell lines Figure 3
Silencing and reactivation in HIV-rtTA SupT1 cell lines. The HIV-rtTA SupT1 cell lines F7 and B9 were induced with 
dox or with dox in combination with the indicated activators. DMSO is the solvent for genistein and therefore used as an addi-
tional control. Statistical significance was determined with a two-tailed student's T test for each combination versus dox alone 
(GraphPad Prism). Significant changes (P-value < 0.05) are indicated with asterisks.
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Latent HIV-1 infection in SupT1 T cells Figure 4
Latent HIV-1 infection in SupT1 T cells. TNFα-induced reactivation of silent HIV-1 proviruses in SupT1 cells was ana-
lyzed by determining the percentage of CA-p24 producing cells by intracellular FACS analysis. (A) After a single round infection 
with the LAI isolate, the culture was split and one culture activated for 24 h with TNFα and the other used as a control. (B) 
The control culture was maintained for one week and split again into a TNFα treated and control culture. Statistical signifi-
cance was determined with a two-tailed student's T test (GraphPad Prism).
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Latent HIV-1 and HIV-rtTA infection in SupT1 T cells Figure 5
Latent HIV-1 and HIV-rtTA infection in SupT1 T 
cells. TNFα-induced reactivation of silent HIV-1 proviruses 
in SupT1 cells was analyzed by determining the percentage of 
CA-p24 producing cells by intracellular FACS analysis. After 
a single round infection with HIV-1 (LAI isolate) or the HIV-
rtTA-Tatwt, each culture was split and either activated for 24 
h with TNFα or not. The fold TNFα activation is the per-
centage CA-p24 positive cells in the culture with TNFα 
divided by the percentage of CA-p24 positive cells in the 
control culture.
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similar phenomenon for the wild-type HIV-1 LAI isolate
in these SupT1 cells. In addition, it has been demon-
strated that HIV-1 uses the cellular miRNA machinery to
maintain proviral latency in resting cells [40] and it has
been shown that the NF-κB sites in the LTR promoter can
be used for maintenance of latency [41,42].
Analysis of the integration sites of HIV-rtTA in these cell
lines showed only a weak positive correlation between the
number of integration sites and the ability to response to
dox addition. We also did not observe striking correla-
tions between dox response and local genomic DNA fea-
tures around the integration site, but a significantly larger
sample number is required to identify such correlations.
The latent provirus could be activated by TNFα, a com-
monly used reagent to reduce HIV-1 latency, and by gen-
istein and 5-Aza that alter DNA methylation.
Combinations of these reagents further increased the level
of provirus activation, thus indicating an additive effect.
In contrast, the regular T cell activators PMA and IL2,
which can be used for HIV-1 reactivation in resting cells,
have no (additional) effects in these SupT1 cell lines.
Huang et al. recently demonstrated that miRNAs contrib-
ute to latency in resting cells and that activation of the
cells by PMA and IL2 reactivates transcription [40]. This
activation does not occur in SupT1 cells, in agreement
with their activated state. These combined results suggest
the presence of different cellular reservoirs for HIV-1Retrovirology 2008, 5:37 http://www.retrovirology.com/content/5/1/37
Page 8 of 13
(page number not for citation purposes)
latency. Each reservoir may require a specific activation
strategy. This means that therapy that aims to purge these
latent viruses will be more difficult, and this could explain
why attempts thus far have been unsuccessful.
To confirm these latency properties for wild-type HIV-1,
we set up a single cycle infection assay and analyzed pro-
viral activity upon TNFα addition. Despite this more indi-
rect analysis, TNFα increased the percentage of virus-
producing cells 2 to 3 fold in infections with wild-type
HIV-1 (LAI isolate) in SupT1 and Jurkat cells. These results
are in agreement with another study [43] that described
strong latency effects with HIV-1 based lentiviral vectors
in Jurkat cells and with J-lat cell lines that were generated
by sorting for Jurkat cells with a latent HIV-1 provirus that
can be activated by TNFα [21].
We did not observe any TNFα stimulation in PHA/IL2
activated CD4+ cells and the HTLV-1 infected cell lines
C8166 and MT2. TNFα stimulates proteolytic degradation
of IkB by the proteasome [44-46]. This degradation liber-
ates NF-kB and allows its nuclear translocation and subse-
quent activation of the HIV-1 LTR. TNFα mediated
transcriptional activation of HIV-1 and LTR-driven
reporter constructs has been described in SupT1 [20], Jur-
kat [25], and HeLa cells [47]. TNFα can also activate the
latent HIV-1 cell lines U1 (based on the promonocyte
U937 cell line) and ACH2 cells (based on A3.01) [24,48].
In these cell lines, NF-kB driven expression can overcome
the defective Tat-TAR axis present in these proviruses. The
absence of a TNFα effects in PBMC and in the MT2/C8166
cell lines indicates that it is specific for certain T cell lines,
possibly related to their differentiation stage. For instance,
the SupT1 cell line represents an early stage in T cell devel-
opment and these CD4+ CD8+ cells are relative rare in
PBMC, and even absent in our CD8+-depleted CD4+ prep-
arations. Alternatively, a high level of endogenous NF-kB
or activation of the NF-kB pathway by endogenous TNFα
production by monocytes, which are still present in the T
cells preparations [49], could explain the lack of a TNFα
effect in these assays. In case of the HTLV-1 transformed
cell lines, the absence of a TNFα response could also be
the result of expression of the viral Tax trans-activator pro-
tein, which blocks TNFα activation [50-55].
In HIV-1 infected individuals the number of integrated
HIV-1 DNA copies is generally 100-fold higher than the
number of cells that produce replication-competent virus
after activation (reviewed in [2]). This discrepancy is usu-
ally explained by the prevalence of defective proviral DNA
genomes due to the high error rate of the HIV-1 RT
enzyme and/or activity of gene-modifying enzymes like
APOBEC3G. We could not demonstrate any TNFα effect
in PBMC, but demonstrated with the HIV-rtTA clones that
TNFα stimulation is not sufficient to completely prevent
the establishment of latency. This could mean that latency
also occurs in activated primary cells, providing an alter-
native explanation for the high number of integrated DNA
copies. Furthermore, the generation of the latent reservoir
in resting memory cells is thought to be mainly the result
of reversion of an infected cell from an active state to a
resting state. This means that these cells have to survive
HIV-1 replication and escape from immune recognition
long enough to establish post-integration latency. It seems
likely that this reversion is much easier for HIV-infected
cells that have a latent provirus.
A high frequency of latently infected cells has important
consequences for our understanding of HIV-1 persistence,
especially when present activated T cells. For instance, this
means that far more infected cells will escape from
immune surveillance then previously anticipated and
these cells will also be unresponsive to any drug treat-
ment. Productive infection of activated T cells results in
reduced susceptibility to new infections due to downregu-
lation of CD4 and cell cycle arrest that is imposed by viral
proteins. Activated cells with a latent provirus do not
express viral proteins and these cells can therefore be re-
infected with the same efficiency as uninfected cells. This
makes superinfection a regular event, which is in agree-
ment with recent findings [56,57]. Productive superinfec-
tion will likely reactivate the already present latent
proviral DNA and result in cells that produce two (or even
more) virus strains. Consequently, recombination can
occur at a high frequency. The proviral copies in these cells
have been established at different times, and this allows
the mixing of historical and more recent virus sequences.
Latent HIV-1 infection in various T cell lines Figure 6
Latent HIV-1 infection in various T cell lines. TNFα-
induced reactivation of silent HIV-1 proviruses in the indi-
cated T cell lines was done as described in Figure 4. The fold 
TNFα activation is the percentage CA-p24 positive cells in 
the culture with TNFα divided by the percentage of CA-p24 
positive cells in the control culture.
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In conclusion, we have developed a new HIV-1 latency
model system that uses the dox inducible HIV-rtTA virus
variant. In combination with FACS analysis, this system
allows the quantitative analysis of transcription activation
of HIV-1 from a latent provirus. The HIV-rtTA virus is ide-
ally suited to study the molecular details of the integrated
HIV-LTR promoter in an active and latent state. The sys-
tem can also be used to quickly quantify the effects of reac-
tivation protocols. Unlike other latency cell systems that
were selected for specific reactivation properties (e.g.
TNFα responsiveness in the J-Lat system), our cell clones
are obtained without any selection. Our data indicate that
HIV-1 proviral latency is not restricted to resting cells, but
also apparent in actively dividing cells. In cell culture
clones, we measured a dramatically differential response
of individual cells to dox induction. These observations
are in agreement with a stochastic model of HIV-1 gene
expression that was proposed by Weinberger [58,59]. This
model, based upon a simplified lentiviral vector system
with the Tat-TAR transactivation feedback loop, demon-
strates that stochastic, random fluctuations in the Tat pro-
tein level determine if LTR-mediated transcription will
initiate. We observed similar fluctuations with our replica-
tion competent virus system in which the Tat/TAR feed-
back loop is replaced with an inducible rtTA feedback
loop.
Methods
Cells and viruses
C33A cervix carcinoma cells (ATCC HTB31) [60] were
grown as a monolayer in advanced Dulbecco s minimal
essential medium supplemented with 1% (v/v) fetal calf
serum (FCS), 40 U/mL penicillin, 40 µg/mL streptomycin,
20 mM glucose and minimal essential medium nonessen-
tial amino acids at 37°C and 5% CO2. The cells were
transfected with plasmid DNA of the HIV-1 LAI molecular
clone [61] and doxycycline (dox)-dependent HIV-rtTA
derivatives [26,31,62] by the calcium phosphate method
as described previously [63]. For analysis of the percent-
age of dox-inducible cells, new rounds of infection were
prevented by addition of the entry inhibitor T1249 [64].
The human T lymphocytic cell lines SupT1 (ATCC CRL-
1942) [65], MT2, C8166 and Jurkat (ATCC TIB-152) were
cultured in advanced RPMI 1640 medium (Gibco BRL,
Gaithersburg, MD) supplemented with 1% (v/v) FCS, 40
U/mL penicillin, and 40 µg/mL streptomycin at 37°C and
5% CO2. HIV-1 infections were performed with C33A-
produced virus stocks of the HIV-1 LAI molecular clone
[61].
SupT1 cells transduced with various HIV-rtTA proviruses
(without dox) were used for limiting dilution to obtain
cell clones. Serial dilutions (3-fold) were prepared in 96-
well plates. Fresh medium was added every 10 days. As an
additional control for the presence of the provirus in all
cells, we performed an additional round of limiting dilu-
tion with the HIV-rtTA-shNef clones D2, B9 and F7. All
tested subclones (11 for D2, 6 for B9 and 15 for F7) were
positive in a genomic DNA PCR for the provirus (Table 2).
The frequency of dox-induction was similar to the paren-
tal cell line, although most of the F7 derived subclones
showed relative low induction levels, and only a few F7
subclones showed very high induction (Table 2).
Peripheral blood mononuclear cells (PBMC) were iso-
lated from different healthy donors, and each batch con-
sists of a mixture of four different donors. PBMC were
cultured as the T cell lines cells, but with the addition of
100 U/mL human IL2 after initial PHA (5 µg/mL) stimu-
lation for 2 days. CD4+ cells were isolated by depletion of
CD8+ cells with Dynabeads® M450 CD8 (Dynal Biotech
ASA, Norway) according to the supplier s instructions.
Table 2: Characteristics of second round limiting dilution of 
shNef clones D2, B9 and F7
Clone HIV-rtTA gDNA PCR Intracellular CA-p24 (24 h)
D2-1B + 0.10
D2-2C + 0.02
D2-4A + 0.01
D2-4B + 0.07
D2-5D + 0.04
D2-6D + 0.01
D2-6G + 0.04
D2-7F + 0.02
D2-8C + 0.04
D2-10D + 0.01
D2-12G + 0.01
B9-2F + 2.07
B9-2G + 0.12
B9-3H + 0.51
B9-4E + 0.71
B9-5F + 0.13
B9-11G + 0.29
F7-2B + 0.41
F7-3F + 0.2
F7-3G + 0.74
F7-4C + 0.22
F7-5F + 0.35
F7-5H + 0.11
F7-6B + 1.41
F7-6D + 69.05
F7-7G + 0.18
F7-8F + 14.30
F7-9D + 1.25
F7-10A + 0.11
F7-10E + 15.75
F7-10F + 0.28
F7-10G + 0.41Retrovirology 2008, 5:37 http://www.retrovirology.com/content/5/1/37
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Chemicals
Genistein (Sigma G6649) was prepared as 1000× stock
solution (30 mM) in DMSO. 5-Azacytidine (Sigma
A1287) was prepared as 50× stock solution (500 µM) in
advanced RPMI 1640. TNFα (Invitrogen PHC3015) was
prepared as 2000× stock solution (10 µg/mL) in sterile
milliQ H2O. T1249 (WQEWEQKITALLEQA-
QIQQEKNEYELQKLDKWASLWEWF, Pepscan Therapeu-
tics BV, Lelystad, The Netherlands) was obtained as
10.000× stock solution. Doxycycline (Sigma D9891) was
prepared as a 1000× stock in sterile milliQ water and used
at a final concentration of 1000 ng/mL.
DNA and RNA manipulations
Plasmid preparations were performed using Qiagen isola-
tion kits. A Northern analysis of shRNA was performed as
described previously [31]. Approximately 15 × 106 cells of
the different HIV-rtTA-shNef SupT1 clones were lysed and
RNAs were isolated using the mirVana™ miRNA isolation
kit (Ambion). Gel electrophoresis of 7 µg RNA (3.5 µg
RNA for the transfected controls) was performed on a
15% acrylamide Novex® TBE-Urea gel (Invitrogen) at 180
V in 1×TBE buffer (90 mM Tris, 90 mM boric acid and 2
mM EDTA, pH 8.3). RNA was transferred onto a positively
charged nylon membrane (Boehringer Mannheim) for 2 h
at 80 V and cross-linked to the membrane with a UV
crosslinker (Stratagene). A 19-nt LNA-molecule (Eurogen-
tec) with a sequence similar to the shRNANef target
sequence (5' GTGCCTGGCTAGAAGCACA 3' ; locked
nucleotides are underlined) was used as a probe. The
probe was 5' end labeled using the kinaseMax kit
(Ambion) in the presence of 2 µL of [-32P]ATP (0.37
MBq/µL, Amersham Biosciences) and purified over a
MicroSpin™ G-25 column (GE Healthcare). Prehybridiza-
tion and hybridization was done in ULTRAhyb buffer
(Ambion) at 42°C for 30 min and 18 h, respectively. The
membrane was washed twice at 42°C with low-stringency
buffer (2×SSC, 0.1% SDS). Images were obtained using
the Typhoon Trio phosphorimager (GE Healthcare).
CA-p24 intracellular staining and fluorescence-activated 
cell sorting
Flow cytometry was performed with RD1 or FITC-conju-
gated mouse monoclonal anti-CA-p24 (clone KC57,
Coulter). Cells from a 1 mL culture sample were collected
(4 min 4000 rpm, Eppendorf centrifuge) and fixated in
250 µL 4% formaldehyde for 5 min at room temperature.
The cells were washed with 500-µL BD Perm/Wash™
buffer (BD Pharmingen) and stained for at least 30 min at
4°C in 20 µL of BD Perm/Wash™ buffer and 5 µL of the
appropriate antibody (diluted 1 in 100). Excess antibody
was removed by washing the cells with 500-µL BD Perm/
Wash™ buffer. The cells were collected and resuspended in
750 µL FACS buffer (PBS with 2% FCS). Cells were ana-
lyzed on a FACScalibur flow cytometer with CellQuest Pro
software (BD biosciences, San Jose, CA). Cell populations
were defined based on forward/sideward scattering. Iso-
type controls (clone MsIgG-RD1, Coulter) or uninduced
control cells (minus dox) were used to set markers. The
data from different assays was corrected for between-ses-
sion variation with the factor correction program [66].
CA-p24 Elisa
Culture supernatant was heat inactivated at 56°C for 30
min in the presence of 0.05% Empigen-BB (Calbiochem,
La Jolla, USA). CA-p24 concentration was determined by
a twin-site ELISA with D7320 (Biochrom, Berlin, Ger-
many) as the capture antibody and alkaline phosphatase-
conjugated anti-p24 monoclonal antibody (EH12-AP) as
the detection antibody. Detection was done with the
lumiphos plus system (Lumigen, Michigan, USA) in a
LUMIstar Galaxy (BMG labtechnologies, Offenburg, Ger-
many) luminescence reader. Recombinant CA-p24 pro-
duced in a baculovirus system was used as the reference
standard.
Determination of proviral integration sites
HIV-1 integration sites were determined by two methods:
linker-mediated PCR (LM-PCR) as described [37] and
inside-out PCR (IO-PCR) with minor adaptations on the
original protocol [38]. Briefly, genomic DNA was isolated
with the DNeasy kit (Qiagen). For LM-PCR, 0.5 µg
genomic DNA was cut with SacI and Tru9I and ligated
with primers RJ037 (5' GTA ATA CGA CTC ACT ATA GGG
CTC CGC TTA AGG GAC 3') and RJ038 (5' PO4-TAG TCC
CTT AAG CGG AG-NH2 c6 3'). Subsequently, the mixture
was used as template in a PCR reaction with primers
RJ039 (5' AGT GCT TCA AGT AGT GTG TGC C 3') and
RJ041 (5' GTA ATA CGA CTC ACT ATA GGG C 3'), fol-
lowed by a nested PCR with primers RJ040 (5' GTC TGT
TGT GTG ACT CTG GTA AC 3') and RJ042 (5' AGG GCT
CCG CTT AAG GGA C 3'). All PCR reactions were set up
with 2× reddye™ premix (Thermo Fisher Scientific,
Waltham, USA).
For the inside-out PCR, we digested 25 ng genomic DNA
with PstI, NsiI or both enzymes and allowed self-ligation
after inactivation of the restriction enzymes for 20 min at
80°C by addition of T4 ligase. This ligation mix was used
as template in a PCR reaction with primers A1095 (5'
GGA CAT CAA GCA GCC ATG CAA AT 3') and A2623 (5'
TAT GCA GCA TCT GAG GGC TC 3') for PstI digestions or
A2790 (5' GGA TAG AGA TAA AAG ACA CC 3') and
A2623 for the other enzyme combinations, followed by a
nested PCR with primers A1096 (5' AAA GAG ACC ATC
AAT GAG GAA GCT 3') and A2624 (5' GCA GTT CTT GAA
GTA CTC CG 3') or primers A2596 (5' CAT CAGC CCA
TAT CAC CTA GAA CT 3') and A2624, respectively.Retrovirology 2008, 5:37 http://www.retrovirology.com/content/5/1/37
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Nested PCR products were analyzed by agarose gel elec-
trophoresis and sequenced directly in case a single band
was observed. Otherwise, the PCR products were first
cloned into a Topo vector (Invitrogen) according to the
suppliers instructions and individual clones with an insert
were sequenced [28]. The obtained sequences were
trimmed for primers and HIV-1 sequences and compared
to the human genome using human BLAT search [67] on
the UCSC website [68] and BLAST on the NCBI server
[69].
Single round infection assays
SupT1 cells were infected with HIV-1 virus stocks of the
primary CXCR4-using LAI isolate. After two hours, excess
virus was washed away and the cells were further cultured
in the presence of entry inhibitor T1249 to block subse-
quent rounds of viral entry. The culture was split after 24
h post-infection, and TNFα was added to one culture.
After another 24 h and 48 h, we measured extracellular
CA-p24 production by Elisa in the cell culture medium
and intracellular CA-p24 by FACS analysis.
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